Standard Chem & Pharm CO., LTD. (1720.TW)
TWD 61.0
(-2.09%)
TWD 61.0
(-2.09%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 1.57 Billion TWD | -9.0% |
| 2022 | 1.65 Billion TWD | 39.59% |
| 2021 | 1.24 Billion TWD | 23.33% |
| 2020 | 1.01 Billion TWD | 25.3% |
| 2019 | 808.65 Million TWD | 9.45% |
| 2018 | 727.79 Million TWD | -1.99% |
| 2017 | 756.37 Million TWD | 14.14% |
| 2016 | 688.04 Million TWD | 3.82% |
| 2015 | 666.29 Million TWD | 2.48% |
| 2014 | 527.09 Million TWD | 18.8% |
| 2013 | 516.62 Million TWD | 20.43% |
| 2012 | 477.36 Million TWD | -8.35% |
| 2011 | 475.92 Million TWD | -0.13% |
| 2010 | 482.95 Million TWD | 13.43% |
| 2009 | 417.9 Million TWD | -6.49% |
| 2008 | 444.46 Million TWD | 3.58% |
| 2007 | 437.54 Million TWD | -9.08% |
| 2006 | 487.48 Million TWD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 532.22 Million TWD | 32.95% |
| 2024 Q2 | 473.86 Million TWD | -9.37% |
| 2023 Q4 | 400.57 Million TWD | -20.5% |
| 2023 Q2 | 497.12 Million TWD | 11.32% |
| 2023 Q1 | 446.58 Million TWD | 21.99% |
| 2023 Q3 | 503.89 Million TWD | 1.36% |
| 2023 FY | - TWD | -7.37% |
| 2022 Q4 | 366.07 Million TWD | -31.77% |
| 2022 FY | - TWD | 39.59% |
| 2022 Q3 | 536.51 Million TWD | 13.59% |
| 2022 Q2 | 472.32 Million TWD | 31.12% |
| 2022 Q1 | 360.21 Million TWD | 10.96% |
| 2021 Q3 | 298.36 Million TWD | 4.95% |
| 2021 Q4 | 324.64 Million TWD | 8.81% |
| 2021 Q1 | 335.67 Million TWD | 22.16% |
| 2021 FY | - TWD | 23.33% |
| 2021 Q2 | 284.3 Million TWD | -15.31% |
| 2020 Q1 | 233.77 Million TWD | 17.66% |
| 2020 Q4 | 274.78 Million TWD | 17.39% |
| 2020 Q3 | 234.06 Million TWD | -11.75% |
| 2020 FY | - TWD | 25.3% |
| 2020 Q2 | 265.22 Million TWD | 13.46% |
| 2019 Q2 | 211.75 Million TWD | 20.15% |
| 2019 FY | - TWD | 9.45% |
| 2019 Q4 | 198.68 Million TWD | -8.74% |
| 2019 Q3 | 217.7 Million TWD | 2.81% |
| 2019 Q1 | 176.23 Million TWD | -12.52% |
| 2018 FY | - TWD | -1.99% |
| 2018 Q4 | 201.46 Million TWD | -10.8% |
| 2018 Q3 | 225.85 Million TWD | 16.81% |
| 2018 Q2 | 193.35 Million TWD | 69.23% |
| 2018 Q1 | 114.25 Million TWD | -12.6% |
| 2017 FY | - TWD | 14.14% |
| 2017 Q1 | 130.57 Million TWD | -9.54% |
| 2017 Q4 | 130.73 Million TWD | -51.28% |
| 2017 Q3 | 268.36 Million TWD | 21.87% |
| 2017 Q2 | 220.21 Million TWD | 68.65% |
| 2016 Q2 | 170.2 Million TWD | 13.43% |
| 2016 FY | - TWD | 3.82% |
| 2016 Q1 | 150.05 Million TWD | 15.56% |
| 2016 Q4 | 144.34 Million TWD | -24.96% |
| 2016 Q3 | 192.36 Million TWD | 13.02% |
| 2015 FY | - TWD | 2.48% |
| 2015 Q4 | 129.85 Million TWD | -19.69% |
| 2015 Q3 | 161.69 Million TWD | -3.24% |
| 2015 Q2 | 167.11 Million TWD | -4.05% |
| 2015 Q1 | 174.16 Million TWD | 27.56% |
| 2014 Q4 | 136.53 Million TWD | -15.96% |
| 2014 FY | - TWD | 18.8% |
| 2014 Q1 | 151.69 Million TWD | 98.27% |
| 2014 Q2 | 166.81 Million TWD | 9.97% |
| 2014 Q3 | 162.46 Million TWD | -2.61% |
| 2013 Q4 | 76.51 Million TWD | -32.94% |
| 2013 FY | - TWD | 20.43% |
| 2013 Q3 | 114.08 Million TWD | -21.31% |
| 2013 Q1 | 184.19 Million TWD | 70.75% |
| 2013 Q2 | 144.97 Million TWD | -21.29% |
| 2012 Q3 | 125.96 Million TWD | 19.37% |
| 2012 Q4 | 107.87 Million TWD | -14.36% |
| 2012 Q2 | 105.52 Million TWD | 7.42% |
| 2012 FY | - TWD | -8.35% |
| 2012 Q1 | 98.23 Million TWD | -40.25% |
| 2011 Q3 | 104.35 Million TWD | -1.58% |
| 2011 Q4 | 164.4 Million TWD | 57.55% |
| 2011 FY | - TWD | -0.13% |
| 2011 Q1 | 96.1 Million TWD | -17.35% |
| 2011 Q2 | 106.02 Million TWD | 10.33% |
| 2010 Q1 | 108.1 Million TWD | 0.0% |
| 2010 FY | - TWD | 13.43% |
| 2010 Q4 | 116.27 Million TWD | -2.47% |
| 2010 Q3 | 119.21 Million TWD | -6.79% |
| 2010 Q2 | 127.89 Million TWD | 18.31% |
| 2009 FY | - TWD | -6.49% |
| 2008 FY | - TWD | 3.58% |
| 2007 FY | - TWD | -9.08% |
| 2006 FY | - TWD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Grape King Bio Ltd | 2.88 Billion TWD | 45.269% |
| Maywufa Company Ltd. | 239.81 Million TWD | -558.417% |
| ScinoPharm Taiwan, Ltd. | 819.15 Million TWD | -92.757% |
| Lotus Pharmaceutical Co., Ltd. | 6.87 Billion TWD | 77.02% |
| LIWANLI Innovation Co., Ltd. | 6.81 Million TWD | -23086.138% |
| YungShin Global Holding Corporation | 1.35 Billion TWD | -16.327% |
| PhytoHealth Corporation | -20.69 Million TWD | 7728.64% |
| SCI Pharmtech, Inc. | 529.61 Million TWD | -198.138% |
| Formosa Laboratories, Inc. | 1.16 Billion TWD | -35.732% |
| PharmaEssentia Corporation | -671.48 Million TWD | 335.147% |
| Bora Pharmaceuticals Co., LTD. | 5.73 Billion TWD | 72.464% |